Liquidia Q3 2026 Earnings Date & Estimates

Liquidia (NASDAQ:LQDA) is a biopharmaceutical company focused on developing and commercializing therapies for patients with pulmonary hypertension and other serious cardiopulmonary diseases. The company is headquartered in Research Triangle Park, North Carolina, and uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition for inhaled and injectable medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder formulation of treprostinil delivered through a proprietary inhaler. The U.S. Food and Drug Administration approved Yutrepia for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease in adults. The product is intended to provide a convenient inhaled treatment option designed to improve exercise ability and reduce disease progression.

The company also maintains a pipeline of additional therapies based on treprostinil and its PRINT technology, including investigational formulations intended to address unmet needs in pulmonary vascular disease. Liquidia was founded in 2004 and became a publicly traded company in 2018. Its activities primarily serve patients and healthcare providers in the United States, with potential international opportunities dependent on future regulatory approvals and commercialization arrangements.